Indications -- cardiovascular Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- cardiovascular

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	9/8/2004 6:05:26 AM
From: nigel bates	of 214

Nicox launches study of HCT 3012 vs rofecoxib impact on blood pressure PARIS (AFX) - Pharmaceuticals developer NicOx SA (Paris: FR0000074130 - news) said it has started a comparative clinical study to compare the effects of HCT 3012 and rofecoxib on arterial blood pressure in patients with mild essential hypertension. The aim of the study is to provide definitive proof of data observed in analysis of the OASIS pivotal Phase II trial in patients treated for osteoarthritis. This analysis suggested that HCT 3012 decreased systolic blood pressure on average by 3mm Hg, while rofecoxib tended to raise systolic blood pressure by a similar extent, NicOx said. The study will be conducted at the University of Pennsylvania, with Professor Garrett FitzGerald as the Principal Investigator. Results are expected in the first quarter of 2005, the company said. Manufacturers of treatments based on rofecoxib include Pfizer Inc (NYSE: PFE - news) . HCT 3012 is the same as AZD382, which AstraZeneca PLC (LSE: AZN.L - news - msgs) decided last September not to advance to Phase III trials. Nicox subsequently reacquired rights to the Cinod class of compounds, of which NCT 3012 is one...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next